Compound E, chemically designated as 209986-17-4 (CAS), represents a significant investigation within the field of Alzheimer's illness research. This γ-secretase modulator was initially developed as a possible therapeutic treatment aimed at reducing the generation of amyloid-beta peptides, which are believed to be key contributors to the formation